# Milky Plasma, Murky Diagnosis: Urgent Plasma Exchange for Severe Hypertriglyceridemia‐Induced Hyperviscosity Without Pancreatitis, but With Myocardial Infarction

**Authors:** Catherine Bodnar, Christina Hughey, Ariel Bodker, Chinelo P. Onyenekwu

PMC · DOI: 10.1002/jca.70095 · Journal of Clinical Apheresis · 2026-02-18

## TL;DR

This paper presents a case of severe high triglycerides causing heart symptoms and highlights plasma exchange as an effective treatment even without typical signs like pancreatitis.

## Contribution

The study emphasizes the under-recognized use of plasma exchange for hypertriglyceridemia-induced hyperviscosity without pancreatitis.

## Key findings

- Plasma exchange rapidly reduced triglyceride levels and resolved hyperviscosity symptoms in the index case.
- Published cases show consistent success of plasma exchange for hypertriglyceridemic hyperviscosity without pancreatitis.
- The paper advocates for early plasma exchange in symptomatic hyperviscosity regardless of pancreatitis presence.

## Abstract

Severe hypertriglyceridemia can increase the risk of acute pancreatitis, but also clinically significant hyperviscosity syndrome characterized by the typical signs of neurologic and visual manifestations. Hyperviscosity syndrome is a well‐established medical emergency. However, hyperviscosity syndrome induced by hypertriglyceridemia may be under‐recognized, particularly when pancreatitis and other classical signs of hyperviscosity syndrome are absent. We describe an index case of extreme hypertriglyceridemia presenting with cardiorespiratory symptoms (chest pain and dyspnea) due to suspected hyperviscosity, but without clinical or radiographic evidence of pancreatitis, successfully treated with therapeutic plasma exchange (TPE). We then review the limited, but growing body of published case reports describing TPE for hypertriglyceridemic hyperviscosity without acute pancreatitis. Across cases, TPE reliably achieved rapid triglyceride reduction and resolution of hyperviscosity symptoms. This review highlights diagnostic challenges, therapeutic indications, and the rationale for early TPE in symptomatic hyperviscosity even when pancreatitis is not present.

## Linked entities

- **Diseases:** hypertriglyceridemia (MONDO:0005347), pancreatitis (MONDO:0004982), myocardial infarction (MONDO:0005068)

## Full-text entities

- **Genes:** MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, LPL (lipoprotein lipase) [NCBI Gene 4023] {aka HDLCQ11, LIPD}
- **Diseases:** heart failure (MESH:D006333), elevation (MESH:D006937), type 2 diabetes mellitus (MESH:D003924), hypergammaglobulinemia (MESH:D006942), Waldenstrom macroglobulinemia (MESH:D008258), Hypertriglyceridemia (MESH:D015228), familial hyperlipoproteinemia type V (MESH:D006954), unstable angina (MESH:D000789), TPE (MESH:D054219), photophobia (MESH:D020795), atherosclerotic cardiovascular disease (MESH:D050197), gammopathies (MESH:D010265), Myocardial Infarction (MESH:D009203), obstructive cardiovascular disease (MESH:D002318), dizziness (MESH:D004244), toxicity (MESH:D064420), mucosal bleeding (MESH:D006470), fatigue (MESH:D005221), myocardial injury (MESH:D009202), chest pain (MESH:D002637), priapism (MESH:D011317), pulmonary emboli (MESH:D020766), hematologic malignancies (MESH:D019337), neurological deficits (MESH:D009461), metabolic disorder (MESH:D008659), metabolic syndrome (MESH:D024821), headache (MESH:D006261), inflammation (MESH:D007249), ACS (MESH:D054058), Hyperviscosity syndrome (MESH:D013577), coronary disease (MESH:D003327), blurred vision (MESH:D014786), dyslipidemia (MESH:D050171), blood malignancies (MESH:D009369), dyspnea (MESH:D004417), multiple myeloma (MESH:D009101), hypertriglyceridemic hyperviscosity (MESH:D064250), neurological/central nervous system deficits (MESH:D002493), NSTEMI (MESH:D000072658), Pancreatitis (MESH:D010195), angina (MESH:D000787), abdominal pain (MESH:D015746)
- **Chemicals:** lipid (MESH:D008055), heparin (MESH:D006493), Icosapent Ethyl (MESH:C035276), Rosuvastatin (MESH:D000068718), ACD-A (-), TG (MESH:D013866), apixaban (MESH:C522181), insulin (MESH:D007328), cholesterol (MESH:D002784), Risankizumab (MESH:C000601773), oxygen (MESH:D010100), Fenofibrate (MESH:D011345), Ezetimibe (MESH:D000069438), sirolimus (MESH:D020123), Triglyceride (MESH:D014280)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12917290/full.md

## References

17 references — full list in the complete paper: https://tomesphere.com/paper/PMC12917290/full.md

---
Source: https://tomesphere.com/paper/PMC12917290